Comparative study of kanamycin sulphate microparticles and nanoparticles for intramuscular administration: preparation <i>in vitro</i> release and preliminary <i>in vivo</i> evaluation

Mustafa, Sanaul; Vk, Devi; Rs, Pai

doi:10.1080/02652048.2016.1248511

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differential virulence of Mtb strains was observed in Wistar rats as judged by bacterial loads developed in the lung and rate of clearance, but rats exposed to a low-dose infection eventually began clearing even Mtb HN878, suggesting this rat could be developed into a LTBI model. Investigators exploring alternative methods for drug delivery, including respirable microspheres loaded with RIF or other anti-TB compounds, also often utilize the rat model (Hirota et al, 2013;Mustafa et al, 2016;Maeda et al, 2019). Infant, prepubescent, and adult minipigs have been infected with Mtb strains and explored as a model of TB and therapeutic treatment (Gil et al, 2010;Ramos et al, 2017).…”

Section: Other In-vivo Models Intended For Tb Drug Developmentmentioning

confidence: 99%

One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics

Yang

Wang

Wen

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Tuberculosis (TB) remains a global health problem despite almost universal efforts to provide patients with highly effective chemotherapy, in part, because many infected individuals are not diagnosed and treated, others do not complete treatment, and a small proportion harbor Mycobacterium tuberculosis (Mtb) strains that have become resistant to drugs in the standard regimen. Development and approval of new drugs for TB have accelerated in the last 10 years, but more drugs are needed due to both Mtb’s development of resistance and the desire to shorten therapy to 4 months or less. The drug development process needs predictive animal models that recapitulate the complex pathology and bacterial burden distribution of human disease. The human host response to pulmonary infection with Mtb is granulomatous inflammation usually resulting in contained lesions and limited bacterial replication. In those who develop progressive or active disease, regions of necrosis and cavitation can develop leading to lasting lung damage and possible death. This review describes the major vertebrate animal models used in evaluating compound activity against Mtb and the disease presentation that develops. Each of the models, including the zebrafish, various mice, guinea pigs, rabbits, and non-human primates provides data on number of Mtb bacteria and pathology resolution. The models where individual lesions can be dissected from the tissue or sampled can also provide data on lesion-specific bacterial loads and lesion-specific drug concentrations. With the inclusion of medical imaging, a compound’s effect on resolution of pathology within individual lesions and animals can also be determined over time. Incorporation of measurement of drug exposure and drug distribution within animals and their tissues is important for choosing the best compounds to push toward the clinic and to the development of better regimens. We review the practical aspects of each model and the advantages and limitations of each in order to promote choosing a rational combination of them for a compound’s development.

show abstract

Section: Other In-vivo Models Intended For Tb Drug Developmentmentioning

confidence: 99%

One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics

Yang

Wang

Wen

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…EPNs can be used in aqueous solution of DOX antitumor drug with enhanced oral bioavailability [64]. KS-loaded PLGA vitamin-E-TPGS microparticles (MPs) and nanoparticles (NPs) showed rapid renal clearance, which results in serious nephrotoxicity/ototoxicity [65]. KS is polycationic and shows poor oral absorption half-life (2.5 h).…”

Section: Sodium-plga Hybrid Nanoparticlesmentioning

confidence: 99%

Chronic Kidney Diseases and Nanoparticle Therapeutics

Upadhyay¹

2017

J Tissue Sci Eng

View full text Add to dashboard Cite

Present review article describes main causes of chronic kidney disease a major health problem public health problem round the globe. Disease has multiple etiologies related to sequential pathophysiological stages. It has major concern with chronic changes in renal structure and that severely alter glomerular filtration rate in patients. This article explains CKD biomarkers in brief i.e., serum creatinine, periostin, a matricellular protein discoidin domain receptor 1 (DDR1), a transmembrane collagen receptor of the tyrosine kinase family, Phospholipase D4 (PLD4) renal biomarkers, metabolic biomarkers. The main focus was given on use of nanoparticles for CKD therapeutics. This article describes various metal and metal oxide nanaoparticles, such as cuprous oxide (CONPs), super paramagnetic iron oxide (new SPIO) nanoparticles, silica-coated iron oxide nanoparticle, Vanadium oxide nanoparticles (VONPs, Titanium dioxide and gold, calcifying nanoparticles, colloidal protein-mineral nanoparticles, Liposomal nanoparticles, MITO-Porter, SB-coated NPs, ASc-loaded polymeric nanoparticles, Carbon-coated iron nanocrystal, Nanodiamonds, Sodium-PLGA hybrid nanoparticles, Epidermal growth factor receptor (EGFR)-targeted chitosan (CS) nanoparticles, Photocaged nanoparticles, Mesoporous silica nanoparticles (MSNs Quantum dots (QDs) which are used for drug delivery patients. For successful management of disease progression of diseases, symptoms should analyze by good physician at an eerily stage, by using highly efficacious, sensitive and specific CKD markers. All factors must include knowing the status of disease and chemotherapeutics by using low toxic nanoparticles. Before being used nanoparticles should evaluate in experiment animal models. For future therapeutics metabolomics, kidney transplants and good wound healers are required.

show abstract

Nanoweapons Against Tuberculosis

Jampílek

Kráľová

2020

Nanoformulations in Human Health

View full text Add to dashboard Cite

Comparative study of kanamycin sulphate microparticles and nanoparticles for intramuscular administration: preparation in vitro release and preliminary in vivo evaluation

Cited by 4 publications

References 35 publications

One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics

One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics

Chronic Kidney Diseases and Nanoparticle Therapeutics

Nanoweapons Against Tuberculosis

Contact Info

Product

Resources

About